Pharmacological Management of Heart Failure

Correct Answer

C — Torsemide

Rationale

Torsemide is a loop diuretic, in the same class as furosemide and bumetanide. Loop diuretics are named for their site of action in the thick ascending limb of the loop of Henle in the kidney. Spironolactone and eplerenone are both mineralocorticoid receptor antagonists — they block the aldosterone receptor in the kidney's collecting duct and heart tissue. Hydrochlorothiazide is a thiazide diuretic that acts at the distal convoluted tubule, a different nephron segment from the loop of Henle. Knowing the class label for each drug is sufficient to answer this question.

Correct Answer

A — Eplerenone

Rationale

Eplerenone is a selective mineralocorticoid receptor antagonist. The word selective distinguishes it from spironolactone, which is also a mineralocorticoid receptor antagonist but additionally binds androgen and progesterone receptors — a lack of selectivity that causes gynecomastia and breast tenderness as side effects. Eplerenone's selectivity for the mineralocorticoid receptor means it avoids these sex-hormone-related side effects. Furosemide, torsemide, and bumetanide are all loop diuretics — they act at the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle, a distinct mechanism from mineralocorticoid receptor antagonism.

Correct Answer

D — Bumetanide

Rationale

Bumetanide is a loop diuretic, in the same class as furosemide and torsemide. The three loop diuretics used in heart failure — furosemide, torsemide, and bumetanide — all block the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle. Spironolactone and eplerenone are both mineralocorticoid receptor antagonists. Chlorthalidone is a thiazide-like diuretic that acts at the distal convoluted tubule, a different site in the nephron. Knowing the class label for each drug is sufficient to answer this question.

Correct Answer

B — Spironolactone additionally binds androgen and progesterone receptors; eplerenone is selective for the mineralocorticoid receptor

Rationale

Spironolactone is a mineralocorticoid receptor antagonist that also cross-reacts with androgen and progesterone receptors due to its steroid-like structure. This cross-reactivity causes gynecomastia (breast tissue enlargement) and breast tenderness, particularly in men, and can also cause menstrual irregularities in women. Eplerenone is a newer mineralocorticoid receptor antagonist engineered for higher selectivity — it has minimal affinity for androgen or progesterone receptors and therefore does not cause these sex-hormone-related side effects. Eplerenone is commonly substituted for spironolactone when these effects occur. Both drugs provide equivalent blockade of the mineralocorticoid receptor itself, including its cardiac fibrosis-promoting effects, which is the source of their survival benefit in heart failure with reduced ejection fraction.

Correct Answer

C — The sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle

Rationale

Loop diuretics are classified as blockers of the sodium-potassium-2-chloride cotransporter located in the thick ascending limb of the loop of Henle. This segment of the nephron normally reabsorbs a large fraction of filtered sodium — blocking it produces a substantial diuresis. Option A describes the transporter blocked by sodium-glucose cotransporter 2 inhibitors such as dapagliflozin and empagliflozin, which act in the proximal convoluted tubule. Option B describes the target of mineralocorticoid receptor antagonists such as spironolactone and eplerenone. Option D describes the sodium-chloride cotransporter targeted by thiazide diuretics such as hydrochlorothiazide and chlorthalidone, which act in the distal convoluted tubule. Knowing the transporter and nephron site is the class-defining vocabulary for loop diuretics.

Correct Answer

A — Mineralocorticoid receptor antagonists

Rationale

Mineralocorticoid receptor antagonists — spironolactone and eplerenone — are classified as one of the four pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction, alongside renin-angiotensin-aldosterone system blockers, beta-blockers, and sodium-glucose cotransporter 2 inhibitors. Their pillar status reflects their proven mortality benefit, which comes primarily from blocking aldosterone-driven cardiac fibrosis rather than from their modest diuretic action. Loop diuretics are the primary agents for relieving congestion symptoms and are used in nearly all symptomatic heart failure patients, but they are not classified as one of the four survival-modifying pillars because they have not demonstrated mortality benefit on their own. Direct renin inhibitors and thiazide diuretics are not among the four pillars.

Correct Answer

D — Furosemide blocks the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle, preventing sodium reabsorption and producing a large loss of sodium and water in the urine that reduces elevated filling pressures

Rationale

The thick ascending limb of the loop of Henle normally reabsorbs a substantial fraction of the sodium filtered by the glomerulus via the sodium-potassium-2-chloride cotransporter. Furosemide blocks this transporter, preventing sodium reabsorption at this site. Because water follows sodium osmotically, blocking this transporter also results in a large loss of water in the urine. This rapidly reduces intravascular volume, which lowers the elevated cardiac filling pressures responsible for the shortness of breath and edema of decompensated heart failure. Loop diuretics are the fastest and most effective agents available for relieving acute congestion. Option A describes the mechanism of mineralocorticoid receptor antagonists. Option B describes the mechanism of angiotensin-converting enzyme inhibitors. Option C describes the mechanism of sodium-glucose cotransporter 2 inhibitors.

Correct Answer

B — The sodium-potassium-2-chloride cotransporter transports potassium along with sodium and chloride; blocking it increases urinary potassium loss, and hypokalemia raises the risk of dangerous arrhythmias

Rationale

The sodium-potassium-2-chloride cotransporter, the target of loop diuretics, transports one sodium ion, one potassium ion, and two chloride ions together. Blocking this transporter therefore prevents the reabsorption of not only sodium and water but also potassium, magnesium, and calcium. The result is increased urinary excretion of all these electrolytes. Potassium loss is the most clinically important consequence: hypokalemia destabilizes the resting membrane potential of cardiac cells, increasing their susceptibility to arrhythmias. In heart failure patients who are already at elevated risk of arrhythmia, loop-diuretic-induced hypokalemia can be particularly hazardous. This is one reason loop diuretics and potassium-sparing agents such as mineralocorticoid receptor antagonists are often used together. Option A incorrectly attributes the potassium loss to secondary aldosterone release. Option C misidentifies both the tubular segment and the mechanism. Option D describes a mechanism involving the renin-angiotensin-aldosterone system that is not the direct explanation for loop-diuretic-induced potassium wasting.

Correct Answer

A — Fluid overload in decompensated heart failure causes edema of the gut wall, which impairs oral furosemide absorption; intravenous administration bypasses this problem and ensures reliable drug delivery

Rationale

Furosemide's oral bioavailability is normally variable, but in patients with decompensated heart failure the problem is compounded by gut wall edema. The same fluid overload that the drug is meant to treat causes congestion and swelling of the intestinal wall, which further reduces and unpredictably delays drug absorption. The result is that oral furosemide may produce an inadequate or delayed diuretic response in the patients who need it most. Intravenous administration bypasses the gut entirely, delivering the drug directly into the bloodstream and ensuring a predictable, rapid onset of diuresis. This is why hospitalized patients with significant fluid overload typically receive intravenous furosemide until they are decongested and their gut absorption can be assumed to be more reliable. Torsemide and bumetanide have more predictable oral absorption than furosemide, which is one reason they may be preferred for long-term outpatient diuretic therapy. Options B, C, and D each describe pharmacological or pharmacokinetic properties that do not account for this difference.

Correct Answer

C — Spironolactone cross-reacts with androgen and progesterone receptors in addition to the mineralocorticoid receptor, producing antiandrogenic effects that cause gynecomastia

Rationale

Spironolactone has a steroid-like structure that allows it to bind not only the mineralocorticoid receptor but also androgen and progesterone receptors. By blocking androgen receptors, spironolactone produces antiandrogenic effects — it antagonizes the normal masculinizing actions of androgens such as testosterone. In men, this antiandrogenic effect disrupts the balance between androgen and estrogen signaling in breast tissue, causing gynecomastia (development of breast glandular tissue) and breast tenderness. This is the most common sex-hormone-related side effect of spironolactone and the most frequent reason for switching patients to eplerenone, which has high selectivity for the mineralocorticoid receptor and minimal affinity for androgen or progesterone receptors. Options A, B, and D each describe mechanisms unrelated to the antiandrogenic activity responsible for this adverse effect.

Correct Answer

D — Eplerenone is selective for the mineralocorticoid receptor and has minimal affinity for androgen and progesterone receptors, so it does not produce the antiandrogenic effects that cause gynecomastia

Rationale

Gynecomastia from spironolactone is caused by its cross-reactivity with androgen receptors, which produces antiandrogenic effects in breast tissue. Eplerenone was developed to address this limitation: its molecular structure gives it high affinity for the mineralocorticoid receptor but minimal affinity for androgen or progesterone receptors. By avoiding these off-target receptor interactions, eplerenone retains the therapeutic benefit of mineralocorticoid receptor antagonism — blocking aldosterone-driven sodium retention and cardiac fibrosis — without the sex-hormone side effects. This makes eplerenone the preferred agent when spironolactone causes intolerable gynecomastia or breast tenderness. Both drugs provide equivalent blockade of the mineralocorticoid receptor itself. Options A, B, and C each describe mechanisms that do not account for the absence of gynecomastia with eplerenone.

Correct Answer

B — Furosemide promotes potassium loss by blocking the sodium-potassium-2-chloride cotransporter, while spironolactone reduces potassium loss by blocking aldosterone — these opposing effects mean the net serum potassium depends on the balance between them and requires monitoring

Rationale

Furosemide and spironolactone have opposite effects on potassium handling. Furosemide blocks the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle, increasing potassium excretion in the urine and tending to lower serum potassium. Spironolactone blocks aldosterone's action in the collecting duct; because aldosterone normally drives potassium excretion, blocking it reduces potassium loss and tends to raise serum potassium. When both drugs are used together, as they frequently are in heart failure, these opposing forces partially offset each other. However, the net effect on serum potassium is unpredictable without monitoring — in some patients the loop diuretic effect dominates and hypokalemia occurs; in others the potassium-sparing effect of spironolactone dominates and hyperkalemia results, particularly when renin-angiotensin-aldosterone system blockers are also present. Regular potassium monitoring is therefore a standard part of heart failure management. Options A, C, and D each mischaracterize one or both drug mechanisms.

Correct Answer

A — Three of these drug classes — the angiotensin-converting enzyme inhibitor, spironolactone, and dapagliflozin — tend to raise potassium, while furosemide lowers it; the opposing forces make the net effect on serum potassium unpredictable without regular monitoring

Rationale

Heart failure with reduced ejection fraction treatment involves multiple drug classes with opposing effects on serum potassium. Angiotensin-converting enzyme inhibitors reduce angiotensin II, which lowers aldosterone and reduces potassium excretion — raising potassium. Spironolactone blocks the mineralocorticoid receptor directly — also raising potassium. Sodium-glucose cotransporter 2 inhibitors such as dapagliflozin modestly raise potassium as well. Together, these three classes tend to push potassium upward. Furosemide pushes in the opposite direction by increasing urinary potassium loss via cotransporter blockade. Beta-blockers have no direct, clinically meaningful effect on potassium in this context. The net effect on serum potassium in any given patient depends on the balance between these opposing forces, kidney function, diet, and other factors — which is why regular monitoring is a standard component of heart failure management. Option B overstates the effect by including beta-blockers and claiming all five drugs raise potassium. Option C mischaracterizes the beta-blocker effect on potassium. Option D reverses the direction of furosemide's potassium effect.

Correct Answer

C — Torsemide and bumetanide have more predictable oral bioavailability than furosemide, producing a more consistent diuretic response after oral dosing

Rationale

Furosemide's oral bioavailability is highly variable — it ranges from roughly 10 to 100 percent across patients and can fluctuate substantially in the same patient depending on food, bowel function, and the degree of gut congestion. This variability means that the same oral dose of furosemide can produce very different diuretic responses on different days. Torsemide and bumetanide are absorbed more consistently after oral dosing, producing a more predictable diuretic effect. For outpatients who are managing their fluid balance chronically, this consistency can translate to more stable symptom control. Furosemide remains the most widely used loop diuretic overall, largely due to familiarity and cost, but torsemide and bumetanide are reasonable alternatives for outpatient management, particularly in patients who experience fluctuating diuretic responses on furosemide. Options A, B, and D each describe properties that do not distinguish torsemide and bumetanide from furosemide in the way described.

Correct Answer

B — Furosemide blocks the sodium-potassium-2-chloride cotransporter, increasing urinary potassium loss and causing hypokalemia, which lowers the threshold for dangerous cardiac arrhythmias

Rationale

Furosemide blocks the sodium-potassium-2-chloride cotransporter in the thick ascending limb of the loop of Henle, preventing the reabsorption of sodium, potassium, and chloride. The resulting increase in urinary potassium loss lowers serum potassium levels. Potassium is a major determinant of the resting membrane potential of cardiac cells — when potassium falls, the cell membrane becomes less stable and more susceptible to spontaneous depolarization, increasing the risk of arrhythmias such as premature ventricular contractions and, in severe hypokalemia, ventricular fibrillation. This is why potassium monitoring is standard practice for patients on loop diuretics, and why adding a potassium-sparing agent such as a mineralocorticoid receptor antagonist can be protective. Option A misattributes the arrhythmia risk to aldosterone rather than to hypokalemia itself. Option C incorrectly attributes the sodium-potassium adenosine triphosphatase pump inhibition to furosemide — that mechanism belongs to digoxin. Option D misidentifies the primary electrolyte disturbance responsible for these arrhythmias.

Correct Answer

D — Spironolactone cross-reacts with androgen receptors and blocks their activity, producing antiandrogenic effects that disturb the hormonal balance in breast tissue and cause gynecomastia

Rationale

Spironolactone's chemical structure is similar enough to steroid hormones that it binds not only the mineralocorticoid receptor but also androgen and progesterone receptors. By blocking androgen receptors, spironolactone interferes with the normal androgenic signaling that suppresses breast glandular tissue development in men. This antiandrogenic effect shifts the local hormonal balance in breast tissue toward estrogenic stimulation, resulting in gynecomastia and breast tenderness. This is the most common reason patients are switched from spironolactone to eplerenone, which is a more selective mineralocorticoid receptor antagonist with minimal androgen or progesterone receptor affinity and therefore does not cause these sex-hormone-related side effects. Both drugs provide equivalent therapeutic blockade of the mineralocorticoid receptor. Options A, B, and C each describe mechanisms that do not account for spironolactone-induced gynecomastia.

Correct Answer

A — Lisinopril and spironolactone both tend to raise potassium by reducing aldosterone-mediated excretion, while furosemide tends to lower it by increasing urinary loss; the opposing forces make the net effect unpredictable and require regular checks

Rationale

In this three-drug regimen, two classes push potassium upward and one pushes it downward. Lisinopril, an angiotensin-converting enzyme inhibitor, reduces angiotensin II, which lowers aldosterone release and decreases renal potassium excretion — raising serum potassium. Spironolactone directly blocks the mineralocorticoid receptor in the collecting duct, further reducing potassium excretion — also raising potassium. Furosemide blocks the sodium-potassium-2-chloride cotransporter in the thick ascending limb, increasing potassium excretion — lowering potassium. The net result in any individual patient depends on the relative strength of these opposing forces, the patient's kidney function, diet, and other factors. A patient whose potassium has been normal can shift in either direction if doses change, kidney function worsens, or dietary potassium intake changes. This is why monitoring remains necessary even when results have been stable. Options B, C, and D each mischaracterize one or more drug mechanisms.

Correct Answer

C — Intravenous; fluid overload causes edema of the gut wall that impairs oral furosemide absorption, and intravenous administration bypasses the gut to ensure reliable drug delivery and a predictable diuresis

Rationale

Furosemide's oral bioavailability is already variable in healthy individuals, and it worsens further in patients with significant fluid overload. The gut wall itself becomes edematous when venous pressure is elevated, which impairs drug absorption across the intestinal mucosa. A patient with severe decompensated heart failure and anasarca (widespread edema as in this patient) may absorb a fraction of the intended oral dose — or none at all. Intravenous administration delivers furosemide directly into the bloodstream, completely bypassing the gut, and produces a reliable and rapid diuretic response. Torsemide and bumetanide have more consistent oral absorption than furosemide and may be reasonable alternatives for outpatient use, but in the acute hospital setting, intravenous furosemide is the standard approach. Options A, B, and D each attribute the preference to pharmacological differences between intravenous and oral furosemide that do not exist — the drug is identical in both formulations; only the route of delivery differs.